P
olypharmacy is a well-described phenomenon in the Geriatrics literature, with known associations with myriad adverse outcomes 1,2 including falls, [3] [4] [5] [6] disability, 7-9 and hospitalization. [10] [11] [12] Commonly defined as the use of at least 5 medications, 13, 14 polypharmacy is particularly prevalent in adults with heart failure (HF), 15 a condition in which the concurrent use of numerous pharmacological agents is embraced as the primary therapeutic strategy to improve outcomes. 16, 17 This creates an inherent tension in which more medications may reflect guideline-concordant care but may also increase the risk of drug interactions and adverse drug events.
To optimize the outcomes of adults with HF, it is important for providers to consider clinical attributes that can affect the risk-benefit balance when prescribing high numbers of medications. Functional impairment is an important attribute that may identify a subpopulation of individuals with HF in whom the risks of taking many medications may outweigh the benefits. Individuals with impairments in their activities of daily living (ADL; e.g., transferring, eating, dressing) are at greater risk of adverse drug reactions. 9 Moreover, given their shorter life expectancy, 18 individuals with ADL impairments may not derive the same benefit from pharmacological therapy as their healthier counterparts. Accordingly, ADL impairment may help identify a subpopulation of individuals with HF that derives limited benefit (and potentially experiences harm) from taking high numbers of medications.
Whether adults with HF and ADL impairment take fewer medications than those without ADL impairment is unknown. Using National Health and Nutrition Examination Survey (NHANES) data from 2003 to 2014, we assessed the association between ADL impairment and number of medications taken by adults with HF adjusting for confounding variables according to the well-established Andersen conceptual framework of health services utilization. 19 
METHODS

Data Source
Methodology for participant recruitment and data collection in NHANES has been previously described. 20 Briefly, NHANES is a cross-sectional survey with a complex, stratified, multistage probability cluster sampling design that produces aggregate-level national estimates of the noninstitutionalized adult civilian U.S. population. 
Study Population
Study subjects included NHANES participants aged 50 and older with self-reported HF, defined as responding "yes" to the question, "Has a doctor or other health professional ever told you that you had congestive heart failure?" HF has been extensively studied in NHANES, 15, [21] [22] [23] and the specificity of self-reported HF has previously been shown to exceed 99%. 24 We excluded participants with missing data on selfreported HF, disability, or number of medications and those who did not participate in the clinical examination (n = 69). Of 61,087 participants surveyed between 2003 and 2014, we included 947 in this study (Supplemental Figure S1 ).
Measurements
Similar to a prior study, 15 we assessed ADL impairment based on self-report of having difficulty with or being unable to dress oneself, feed oneself, or get in and out of bed.
Medication lists were obtained for all NHANES participants during an in-home interview, during which participants were also asked to show their medication containers for verification. We determined medication count for each participant by counting the number of medications taken according to self-report. We defined polypharmacy according to the commonly used definition of 5 or more medications, 13, 14 a threshold associated with poor outcomes. 25 We classified medications according to the Multum Lexicon Drug Database. 26 We selected covariates according to the Andersen model of healthcare utilization, 19 which incorporates predisposing, enabling, need, and healthcare utilization factors into a conceptual model. Predisposing factors were age, sex, and race. Enabling factors were primary health insurance payer, highest level of education, total annual household income, marital status, and living alone (defined as total number of people in household = 1). Need factors were comorbidity count, smoking status, self-reported change in health from prior year (same, worse, better), frailty as defined according to hypoalbuminemia (albumin ≤3.3 g/dL), 27 and self-reported memory problems (reported as yes or no) as a proxy for cognitive impairment. NHANES lacked robust measures of frailty during the NHANES years included in this study. Although a 4-item frailty phenotype (exhaustion, low physical activity, weakness, "shrinking") has been used in NHANES, factors including exhaustion, low physical activity, and weakness overlap considerably with ADL impairment, 28 whereas shrinking seems to be a unique concept and may be operationalized using serum albumin levels, 27 which are available in NHANES. We accordingly used hypoalbuminemia as a proxy for frailty. Comorbidity count was a count of comorbid conditions (hypertension, diabetes, anemia, asthma, chronic bronchitis, emphysema, coronary artery disease, prior myocardial infarction, prior stroke, thyroid disease, liver disease, cancer, chronic kidney disease, dialysis, hypercholesterolemia, arthritis). We chose comorbid conditions based on their availability in every NHANES cycle included in this study (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) . Healthcare utilization factors included number of contacts with ambulatory healthcare services (including emergency department visits that did not lead to an overnight hospitalization) and all-cause hospitalizations (≥1 overnight stays) during the prior year.
Statistical Analysis
We accounted for the complex survey design of NHANES in all analyses. For variance estimation, we used the Taylor linearization method, a method based on first-order Taylor series linear approximation of the derivative of the logweighted likelihood function. 29 We calculated weighted means with standard deviations for continuous variables and weighted percentages with 95% confidence intervals for categorical variables to summarize study subject characteristics. We used the t-test and Pearson chi-square test to investigate significant differences between groups. We assessed the trend of medication count over time using survey-weighted linear regression.
To determine the independent association between ADL impairment and medication count, we performed sequential Poisson multivariable regression analyses, guided by the Andersen model. 19 We first determined the association between ADL impairment and medication count adjusted only for NHANES cycle. We then added predisposing factors (Model 1) and then enabling factors (Model 2). Because comorbidity count is an especially important need factor that affects number of medications, 30 we added comorbidity count to the model separately (Model 3), followed by the remainder of the need factors (Model 4). Finally, we added healthcare utilization factors (Model 5).
To account for missing covariate values in our regression analysis, we used multiple imputation with chained equations designed for complex survey data. 31 We performed 50 imputations using sampling of estimates from the posterior distribution of model parameters and created pooled estimates by fitting regression models within each of the 50 datasets for imputation-specific estimates and then combined them using Rubin's rules. 32 In the selected sample, 32% of participants had a missing value for at least 1 covariate. The variable with the greatest percentage missing was primary payer (18%).
To determine whether the independent association between ADL impairment and medication count differed in individuals aged 65 and older, a population at especially high risk for adverse drug events requiring medical attention, 33 we performed a sensitivity analysis of sequential Poisson multivariable regression analyses in those aged 65 and older. To determine whether our results would differ if we included only chronic medications, as used in a prior NHANES analysis, 15 we performed a sensitivity analysis in which medication count included only agents taken for at least 2 weeks. To ensure that our models did not result in overdispersion, we also ran the models using negative binomial regression, which revealed nearly identical results.
Finally, we used Wald tests to determine the presence of effect modification from factors chosen a priori. We performed tests for interactions between ADL impairment and 3 or more hospitalizations in the prior year, declining selfreported health status, and cognitive impairment.
We used 2-sided hypothesis testing and p < .05 to determine statistical significance. We managed the data in SAS version 9.4 (SAS Institute, Inc., Cary, NC) and performed statistical analysis using Stata version 14 (Stata Corp., College Station, TX).
RESULTS
Our study sample of 947 participants represented a noninstitutionalized adult population in the United States of approximately 4.6 million adults with HF. The mean age of our cohort was 70 (95% confidence interval = 69.3-70.7), with an even distribution of men and women (Table 1) . Other baseline characteristics are shown in Table 1 . Participants with ADL impairment were more likely to be dual Medicare and Medicaid beneficiaries and less likely to be married than those without.
The mean number of comorbid conditions in our sample was 4.7. Participants with ADL impairment had approximately 25% more comorbid conditions (5.6 vs 4.5, p = .001); were more likely to have a history of stroke, asthma, chronic bronchitis, and anemia (Supplementary  Table S1 ); and more likely to have hypoalbuminemia (Table 1) .
Approximately half of the study participants reported that their health status was the same as it had been the prior year (Table 1) . Those with ADL impairment were more likely to report that their health status had declined over the prior year. The overall prevalence of cognitive impairment in the study sample was 24%, and cognitive impairment was more common in those with ADL impairment. With regard to healthcare utilization over the prior year, 39% of participants had had contact with ambulatory healthcare services at least 10 times, and 9% had been hospitalized at least 3 times. Those with ADL impairment were more likely to have had at least 10 contacts with ambulatory healthcare services and to have been hospitalized at least 3 times.
Overall mean medication count was 7.2 ( Table 2 ). The prevalence of polypharmacy, defined as 5 or more medications, was 74%. The full distribution of the medication count is shown in Figure 1 . Participants with ADL impairment had a higher mean medication count (8.5 vs 7.0, p < .001) and were more likely to have polypharmacy (82% vs. 73%, p = .003) than those without ADL impairment. Mean medication count was higher in those with ADL impairment in all age strata (Figure 2A ). Table 2 shows the prevalence of medications according to ADL impairment. The 3 most common medication classes were beta-blockers (61%), diuretics (60%), and angiotensinconverting enzyme inhibitors and angiotensin receptor blockers (58%). The prevalence of these agents did not differ according to ADL impairment. Several agents were more common in those with ADL impairment (proton pump inhibitors, histamine-2 receptor blockers, minerals and vitamins, antidepressants, nonopioid analgesics).
The prevalence of ADL impairment was 11%. Of those with ADL impairment, 55% reported difficulty with transferring (getting in and out of bed), 22% with eating, and 64% with dressing themselves. Mean medication count in individuals with ADL impairment exceeded the mean of those without in the majority of NHANES cycles (Supplementary Table S2 ). Mean medication count increased over time for those without ADL impairment (p for trend = .04) but not those with ADL impairment (p for trend = .67). In a crude model adjusted for survey year only, ADL impairment was associated with 23% more medications (Table 3) , but in the fully adjusted modelaccounting for predisposing and enabling factors, need factors including comorbidity and frailty, and healthcare utilization factors-ADL impairment was not independently associated with medication count. In other words, the number of medications that adults with ADL impairment took was similar to the number that those without ADL impairment took in a fully adjusted model; this was consistent in all age strata ( Figure 2B) .
In a sensitivity analysis of participants aged 65 and older, sequential multivariable regression analysis revealed a pattern similar to that observed in the entire cohort (Supplementary Table S3 ). In a second sensitivity analysis, in which medication count included only agents taken for at least 2 weeks, mean number of medications remained 7.1, and a sequential multivariable regression analysis again revealed a pattern similar to that observed in the entire cohort (Supplementary Table S4) .
None of the a priori-specified interactions were significant (Supplementary Table S5 ) (≥3 hospitalizations in prior year, p for interaction = .40; declining health status over prior year, p for interaction = .66; cognitive impairment, p for interaction = .10).
DISCUSSION
This analysis of NHANES data revealed that adults with HF take many medications irrespective of ADL impairment and that ADL impairment is not independently associated with number of medications taken despite the known association between ADL impairment and adverse drug events and shorter life expectancy. We also found that factors associated with poorer prognosis, including recurrent hospitalization, declining health, and cognitive impairment, did not modify this association. Together, these findings suggest that providers may not integrate functional impairment and overall prognosis into their prescribing practices and may unnecessarily be exposing individuals with HF to risks associated with polypharmacy.
The attendant risks of taking many medications are well described in the Geriatrics literature, with known associations with a number of adverse outcomes, 1,2 including falls, [3] [4] [5] [6] disability, 7-9 and hospitalizations. [10] [11] [12] Consequently, there is an inherent tension between this observation and providing guideline-concordant care to adults with HF, which frequently includes concurrently prescribing various medications for HF, 16 ,17,34 as well as for other common comorbid cardiovascular and noncardiovascular conditions. An individualized assessment of the risks and benefits of initiating, titrating, and discontinuing medications is an important component of safe prescribing practice, as the risks and benefits can differ substantially in different subpopulations. Adults with ADL impairment are a subpopulation in whom the risks of high medication burden may exceed its potential benefit. Adults with ADL impairment are at greater risk of adverse drug events 9 and may be less likely to derive long-term benefit from many of their prescribed medications because of limited life expectancy. 18 Even the benefits of HF medications are not clear [35] [36] [37] Thus, given their risk of harm and attenuated potential for benefit, we hypothesized that ADL impairment would be associated with taking fewer medications after controlling for comorbidity and other confounders. Surprisingly, after adjusting for comorbidity and other confounders using the Andersen framework, 19 we found that ADL impairment was not independently associated (26) 202 (26) 34 (24) .75 Calcium-channel blocker 243 (22) 208 (22) 35 (23) .85 Anticoagulation agent
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with medication count. In other words, adults with HF who had an impairment in transferring, eating, or dressing took as many medications as those without such impairments, after accounting for comorbidity burden. Although there is the possibility of residual confounding, our findings suggest that providers may not consider functional impairment when prescribing medications to adults with HF and thus may be exposing patients to an increased to risk of adverse outcomes. Given the well-known association between recurrent hospitalizations and shorter survival, we further examined whether having 3 or more hospitalizations, which is associated with a median survival of less than 1 year, 38 modified the association between ADL impairment and medication count. We found no effect. Declining self-reported health, a harbinger of shorter survival, 39 also had no effect on this relationship. Finally, cognitive impairment, which is independently associated with adverse drug events, 40 did not affect this relationship either. Taken together, these data strengthen the supposition that providers may not consider important factors that ultimately affect the risk-benefit ratio of prescribing medications. Although much has been written about the importance of incorporating overall prognosis, functional impairment, and cognition into decisions regarding device implantation 41, 42 and advanced HF therapies such as left ventricular assist devices, 43 less has been written about pharmacological therapy despite its significant population-based implications. Medications have attendant risks as well, even if not to the degree of device implantation or surgery; adverse drug events cause more than 700,000 emergency department visits per year in the United States. 44 Thus, in addition to ADL impairment, factors such as recurrent hospitalizations, which are a marker of advanced disease and overall prognosis, declining selfreported health, and cognitive impairment, probably warrant consideration when prescribing medications to adults with HF.
The underlying reasons for our observations are not clear. One possibly explanation for why number of medications did not differ according to ADL status in adults with HF is that prescribers do not appreciate the importance of incorporating functional impairment and prognosis into decision-making. Functional impairment as it relates to ADLs may be challenging for clinicians to determine from the symptoms and physical limitations that frequently result from HF. Consequently, it may not be apparent to clinicians whether more-aggressive treatment of HF (and other comorbid conditions) is beneficial or harmful. Another possibility for our findings is that, in the era of subspecialty care, with the average adult seeing a median of 7 different providers per year, 45 physicians are prescribing medications for conditions within the scope of their expertise without consideration for other important factors such as ADL impairment and total medication burden. Our study revealed that several classes of noncardiovascular agents were more common in individuals with ADL impairment than those without. Thus, developing and studying strategies to ensure safe and appropriate use of these agents through improved communication between specialties and implementation of more-comprehensive medication reconciliation efforts by subspecialists, such as cardiovascular clinicians, are needed. Our data underscore the need to emphasize the potential risks of high medication burden to clinicians caring for adults with HF. Consideration of the effect of a high burden of medication on cross-disease or universal health outcomes such as health-related quality of life and daily functioning are similarly important and warrant novel strategies to incorporate these factors into medical decision-making. 46, 47 Future research would benefit from a focus on developing strategies to identify individuals at high risk of polypharmacy and its adverse outcomes, as well as strategies to mitigate its effects when polypharmacy is present. Deprescribing has emerged as a potential strategy to reduce medication burden, 48 but it is unclear which individuals would benefit from this strategy and at what point in their disease trajectory it warrants consideration. Whether adults with HF with ADL impairment, who are at high risk of adverse drugs events and have limited life expectancy, are a subpopulation in whom deprescribing would be beneficial is unknown and is an area for future investigation.
A major strength of this study is its generalizability, because NHANES is a nationally representative sample of the adult noninstitutionalized population of the United States. There are also several limitations worth noting. Because this was a cross-sectional study, we could not determine the causal relationship between variables. Details of medication dose, frequency, and indication were not available; whether these differed according to ADL impairment was unknown. Data regarding severity of various comorbid conditions, which could have contributed to residual confounding by indication, were not available. In addition, a number of comorbid conditions, including depression and neuromuscular conditions, were not routinely assessed during the study period and thus were not included in the analysis; these could have affected our findings. NHANES lacks data on hygiene, toileting, and bathing, so our definition of ADL impairment did not include these, which may have affected the patterns observed. NHANES also lacks a robust unambiguous metric for frailty; although ADL impairment and hypoalbuminemia can account for several aspects of frailty, we cannot be sure that we fully adjusted for frailty. We also did not have data about the severity (New York Heart Association class) or subtype of HF. Because the efficacies of pharmacological therapy for HF with reduced ejection fraction and HF with preserved ejection differ, medication count and its association with ADL impairment may have differed between HF subtypes. Finally, NHANES data are predominantly ascertained according to self-report, which can introduce recall bias. Self-report as a means of identifying HF has demonstrated excellent specificity but limited sensitivity 24 ; consequently, this cohort may not have included individuals with less-severe HF. Self-report as a means of identifying other comorbid conditions have demonstrated highly variable diagnostic performance metrics, 49 and this is thus another important limitation.
In conclusion, after adjusting for confounders including comorbidity, we found that adults with HF with ADL impairment take as many medications as those without ADL impairment. This observation remained even in the setting of recurrent hospitalizations, declining health, and cognitive impairment. This suggests that providers may not sufficiently consider ADL impairment, which can be challenging to differentiate from physical limitations related to HF symptoms, or prognosis when prescribing medications to adults with HF and thus may be unnecessarily exposing individuals to risk of adverse outcomes.
